Reelin and glutamic acid decarboxylase 67 (GAD67) expression down-regulation in GABAergic interneurons of mice exposed to protracted treatment with L-methionine (MET) is attributed to RELN and GAD 67 promoter cytosine-5-hypermethylation. This process recruits various transcription repressor proteins [methyl-CpG binding protein (MeCP2) and histone deacetylases (HDACs)] leading to formation of transcriptionally inactive chromatin. Here, we tested the hypothesis that RELN and GAD 67 promoter cytosine-5-hypermethylation induced by a protracted MET treatment is reversible and that repeated administration of HDAC inhibitors influences this process by an activation of DNA-cytosine-5-demethylation. In the frontal cortices of mice receiving MET (5.2 mmol/kg twice a day for 7 days) and killed at 1, 2, 3, 6, and 9 days during MET washout, we measured RELN (base pairs ؊414 to ؊242) and GAD 67 (base pairs ؊1133 to ؊942) promoter methylation and MeCP2 bound to methylated cytosines of RELN (base pairs ؊520 to ؊198) and GAD 67 (base pairs ؊446 to ؊760) promoters. Levels of RELN and GAD 67 promoter hypermethylation induced by 7 days of MET treatment declines by Ϸ50% after 6 days of MET withdrawal. When valproate (VPA) (2 mmol/kg) or MS-275 (0.015-0.12 mmol/ kg), two structurally unrelated HDAC inhibitors, was given after MET treatment termination, VPA and MS-275 dramatically accelerated RELN and GAD 67 promoter demethylation in 48 -72 h. At these doses, VPA and MS-275 effectively increased the binding of acetylhistone-3 to RELN and GAD 67 promoters, suggesting that histone-3 covalent modifications modulate DNA demethylation in terminally differentiated neurons, supporting the view that, directly or indirectly, HDAC inhibitors may facilitate DNA demethylation.
T
he down-regulation of glutamic acid decarboxylase 67 (GAD 67 ) and reelin expressed in telencephalic GABAergic neurons is a characteristic and prominent neuropathological alteration observed in patients with schizophrenia (SZ) and bipolar (BP) disorder with psychosis (1) (2) (3) (4) (5) (6) (7) (8) .
GAD 67 is one of the two molecular forms of GABA-synthesizing enzymes and plays an important role in maintaining GABA steady-state levels at GABAergic synapses (9) . Reelin is a 400-kDa glycoprotein synthesized by cortical GABAergic neurons. On secretion into the extracellular matrix, reelin adheres to dendritic shafts and spines of pyramidal neurons (10) (11) (12) . Previous experiments have suggested that reelin may play a role in the regulation of event-related protein synthesis in dendritic spines (11) . Reelin has also been implicated in synaptic plasticity and learning and memory functions (10) (11) (12) (13) (14) (15) .
The down-regulation of reelin expression is probably responsible for the decrease in dendritic spine density observed in the frontal cortex (FC) of heterozygous reeler mice and perhaps also in the prefrontal cortex (PFC) of SZ and BP disorder patients (12) . Hence, a deficit in GABAergic transmission because of a decrease of GAD 67 and reelin expression may cause a disruption of the intermittent high-frequency synchronization bursts of cortical pyramidal neuron firing that occurs during cortical function, and an alteration of this firing may play a role in thought disorders and in working memory impairments expressed by SZ and BP patients (16) .
Several lines of evidence suggest that epigenetic mechanisms, including the increase of promoter cytosine-5-methylation at specific CpG islands, are probably associated with reelin and GAD 67 expression down-regulation in psychiatric patients. For example, there is evidence that CpG islands embedded in the RELN promoter are hypermethylated in the PFC of SZ patients (17) (18) (19) .
In the PFC, GABAergic neurons of SZ and BP patients show (i) an increased expression of DNA methyltransferase 1 (DNMT1), the enzyme that catalyzes DNA (cytosine-5) methylation at CpG island-enriched promoter regions (8, 20) ; and (ii) an increased level of S-adenosylmethionine (SAM) (21) , which functions as a methyl donor in DNMT1-mediated cytosine-5-methylation reactions.
We have also reported that the increase of SAM brain content elicited by protracted L-methionine (MET) treatment in mice causes the RELN and GAD 67 promoter hypermethylation that is probably operative in the transcriptional down-regulation of these genes in the FC and perhaps other brain areas of psychotic patients (19, (22) (23) (24) (25) .
Recent studies suggest that in addition to the increased levels of DNMTs and SAM, an active DNA-cytosine-5-demethylase (DNA demethylase) may play an important regulatory role in determining the level of gene-specific cytosine methylation in differentiated somatic cells and also in terminally differentiated neurons (26) (27) (28) . Thus, to study whether hypermethylated RELN and GAD 67 promoters in the brain can be demethylated by the action of a DNA demethylase, we tested in mice (i) whether RELN and GAD 67 promoter hypermethylation induced by protracted MET administration is reversible on MET withdrawal, (ii) and whether the demethylation process can be induced by 2-propylpentanoate (valproate, VPA) or by N-(2-aminophenyl) -4-[N-(pyridin-3-ylmethoxycarbonyl) aminomethyl]benzamide (MS-275), which is also known to inhibit HDACs. VPA is a weak HDAC inhibitor, whereas MS-275, which is structurally unrelated to VPA, is a potent and selective HDAC inhibitor that enters the brain (29) .
In this paper, we report that VPA and MS-275, in doses that increase brain nucleosomal acetylhistone-3 (29) , also accelerate RELN and GAD 67 promoter demethylation, presumably by activating a putative DNA demethylase.
Results
MET Increases RELN and GAD67 Promoter Cytosine-5-Methylation. We assessed DNA cytosine-5 methylation by using a methylation-specific PCR (MSP) technique to measure the methylated and unmethylated cytosines in CpG island-enriched promoter regions of RELN (sequence from Ϫ414 to Ϫ242 bp), GAD 67 (sequence from base pair Ϫ1133 to base pair Ϫ942), and GAD 65 (sequence from base pair 3512 to base pair 3664) (refs. 30 and 31 and GenBank accession no. AB032757, respectively). Because the MPS analysis is not quantitative and provides only a comparative assessment, the methylated/unmethylated status of RELN and GAD 67 promoters was independently quantified by determining the amount of RELN (sequence from base pair Ϫ520 to base pair Ϫ198) and GAD 67 (sequence from base pair Ϫ760 to base pair Ϫ446) CpG island-enriched promoter fragments associated with MeCP2 by using ChIP with a specific MeCP2 antibody coupled to a competitive PCR (25) .
As shown in Fig. 1 , the FC of mice receiving MET (5.2 mmol/kg) s.c. twice daily for 6 days shows a significant and robust increase in methylated cytosine and a concomitant decrease of unmethylated cytosine residues in CpG sites of RELN and GAD 67 promoters. In contrast, this MET treatment failed to change the levels of methylated or unmethylated cytosines in the CpG sites of the GAD 65 promoter region that were analyzed.
The results reported in Fig. 2 are consistent with the data of Fig. 1 and show that in the FC of mice treated with MET (5.2 mmol/kg s.c. twice daily), RELN and GAD 67 promoters express a time-dependent increase of MeCP2 binding that reaches its maximum levels within 6 days of MET treatment.
MET-Induced RELN and GAD67 Promoter Methylation Is Reversed After MET Withdrawal. In mice receiving MET for 7 days, the hypermethylation of RELN and GAD 67 promoters can be reversed after MET withdrawal. Fig. 3 shows that the increased recruitment of MeCP2 to the hypermethylated RELN and GAD 67 promoters elicited by 7 days of MET treatment declines slowly, reaching a 50% reduction after 6 days and approaching steady-state control values only after 9 days of MET withdrawal. Fig. 4 shows that after MET withdrawal, the cytosine-5-methylation at CpG islands of RELN and GAD 67 promoters, measured by the MSP technique, declines with a time course similar to that of the MeCP2 binding.
As in previous studies (22, 24, 25) , protracted daily MET treatments and the consequent RELN and GAD 67 promoter hypermethylation are associated with an Ϸ50% reduction of reelin and GAD 67 expression (Fig. 5) . The expression downregulation of these two proteins is reversed 7 days after MET withdrawal (Fig. 5 ).
VPA and MS-275 Injections After MET Withdrawal Accelerate RELN and
GAD67 Promoter Demethylation. Two chemically unrelated HDAC inhibitors, VPA and MS-275, were tested for their ability to accelerate RELN and GAD 67 promoter demethylation.
In a first group of experiments, VPA and MS-275 were given in doses that (i) maximally acetylate nucleosomal histones in the brain cortex and hippocampus (29) , and (ii) effectively increase the acetylhistone-3 bound to RELN and GAD 67 promoters in the FC (29) . As shown in Figs. 3 and 4, VPA (2 mmol/kg) and MS-275 (0.060 mmol/kg) given to mice for 1-6 days after 67 , and GAD65 promoter fragments were immunoprecipitated with MeCP2 antibody and were quantified by using competitive PCR with internal standards (25) . Depicted are the ratios between the amount of RELN (ᮀ), GAD67 (■), and GAD65 (F) promoters immunoprecipitated with MeCP2 antibody (MeCP2-ChIP) and the amount of the corresponding promoter fragments in the initial nonimmunoprecipitated extract (input). MET was given at dose of 5.2 mmol/kg s.c. twice a day; the last injection of MET was administered 2 h before decapitation. The data represent the mean Ϯ SE of three to five mice. * , P Ͻ 0.01 when 0-and 3-day are compared with 6-and 15-day MET-treated groups (ANOVA followed by Dunnett's test). antibodies. Mice were first treated with MET (5.2 mmol/kg s.c. twice a day, for 7 days) (days Ϫ7 to 0) to obtain an increase of MeCP2 binding to the hypermethylated RELN (A) or GAD 67 (B) promoters in FC. Then, after MET (F) treatment termination (day 0), vehicle (VEH ᭜), VPA (ᮀ) (2 mmol/kg s.c. twice a day), and MS-275 (᭛) (0.12 mmol/kg s.c. once a day) were given to mice for 1, 2, 3, 6, and 9 days. The data represent the mean Ϯ SE of three to five mice. * , P Ͻ 0.01 vs. 7-day MET-treated mice (F); #, P Ͻ 0.01 vs. 3, 6, and 9 days VEH groups; §, P Ͻ 0.01 when 3-and 6-day VPA-or MS-275-treated mice are compared with 3-and 6-day VEH-treated groups (ANOVA followed by Dunnett's test).
termination of a 7-day treatment with MET dramatically (in 48-72 h) accelerated the reversal of FC RELN and GAD 67 CpG island methylation measured (i) as the time course of MeCP2 disassociation from the methylated promoter region of both genes determined by using the quantitative ChIP technique (Fig.  3) , and (ii) by using the MSP technique (Fig. 4) .
In a second group of experiments, we observed that MS-275 stimulates RELN and GAD 67 demethylation in a dose-dependent manner (Fig. 6 ) and that this stimulation can be related to the extent of the increase of acetylhistone-3 at RELN and GAD 67 promoters (29) .
Importantly, we also observed that a single injection of VPA immediately after termination of MET treatment facilitates RELN promoter demethylation (a reduction of Ϸ50%) after 3 days of MET withdrawal. However, as expected, in this case the extent of RELN promoter demethylation is not as large as that obtained by repeatedly injecting VPA (see Figs. 3 and 4) .
MET, at a dose (5.2 mmol/kg s.c. twice a day for 7 days) that induces RELN and GAD 67 promoter hypermethylation in the FC (Fig. 1) also exerts a similar effect in the hippocampus. In the hippocampus, VPA also facilitates RELN promoter demethylation with a time course similar to that found in the FC (MeCP2 ChIP/Input) for RELN promoters: VEH ϭ 0.09 Ϯ 0.005, MET ϭ 0.31 Ϯ 0.035, VEH (MET withdrawal for 3 days) ϭ 0.29 Ϯ 0.018, and VPA (MET withdrawal for 3 days) ϭ 0.08 Ϯ 0.003. However the liver, which expresses a high basal RELN promoter methylation (ratio of MeCP2 ChIP/Input Ϸ 0.8), seems to be unaffected.
Procainamide, in Doses That Inhibit MET-Induced RELN and GAD67 Promoter Cytosine-5-Methylation, Fails to Alter the Time Course of
Their Demethylation. To establish whether the acceleration of RELN and GAD 67 promoter demethylation induced by VPA and MS-275 is related to a reduction of DNMT1 activity, we inhibited this methylation process by administering procainamide (a competitive inhibitor of DNA methyltransferases) (32) . In preliminary experiments, we established that procainamide (0.29 mmol/ kg, four times a day) completely prevents the RELN and GAD 67 promoter hypermethylation induced by 7 days of treatment with MET (not shown). Fig. 7 A and B shows that mice receiving procainamide (0.29 mmol/kg four times a day) during MET withdrawal exhibited an apparent time course of RELN and GAD 67 promoter demethylation comparable to that of mice treated with a vehicle during MET withdrawal. To test whether the dose of procainamide used in these experiments was able to effectively block DNMT1 activity, after 7 days of MET withdrawal we reexposed mice (previously challenged with either procainamide or vehicle for 7 days during MET withdrawal) to MET (5.2 mmol/kg, twice a day). As shown in Fig. 7 C and D, MET reexposure elicits the reappearance of RELN and GAD 67 Fig. 5 .
Reversal of MET-induced reelin and GAD67 expression downregulation after MET withdrawal. (A) Average reelin, GAD 67, and GAD65 protein levels (OD ratios of reelin, GAD67, and GAD65 to ␤-actin) in FC of mice treated with MET (5.2 mmol/kg s.c. twice a day) for 7 days (MET-7d), shaded bars; VEH, open bars; or after 7 days of MET withdrawal (MET-W), filled bars.
* , P Ͻ 0.05 vs. VEH group (Student's t test). (B) Typical Western blots of reelin
and GAD 67/GAD65 with three serial dilutions of the same sample. The intensity of ␤-actin determined on the same blot was used for a comparative estimation of sampling variation. The data represent the mean Ϯ SE of three to five mice. promoter methylation in vehicle-treated but not in procainamide-treated mice. This finding suggests that procainamide, at the doses used in these experiments, is capable of blocking DNMT1 methylation activity.
Discussion
DNA cytosine-5-methylation established during somatic cell division and differentiation is a very stable DNA covalent modification faithfully maintained throughout the lifespan of a cell. However, recent data (26) (27) (28) 33) suggest that in differentiated cells, including terminally differentiated neurons, DNA methylation marking may also undergo rapid changes that are probably mediated by the action of a putative DNA demethylase. Hence, differentiated neurons not only are able to express a maintenance cell type-specific DNA methylation pattern that is a form of genetic inventory at the cellular level but also are likely to express a rapid DNA demethylation process as an aspect of a transient epigenomic response to intracellular or extracellular signals or drugs.
The present study, using two independent but complementary methods to measure promoter cytosine methylation, provides evidence that in the FC of the adult mouse, the robust CpG island hypermethylation of RELN and GAD 67 promoters induced by protracted MET treatment is slowly reversed after MET withdrawal, in Ϸ9 days.
Direct measurements of brain SAM exclude the hypothesis that after MET withdrawal, the long time course of RELN and GAD 67 promoter demethylation is because of an accumulation of FC SAM elicited by 7 days of MET pretreatment. In fact, measurement of FC SAM 12 h after 7 days of MET treatment (22, 24) showed only a slight increase of this methyl group donor. Furthermore, preliminary data suggest that expression of FC DNMT1, which is the most abundant form of DNMT mRNA expressed in the mouse brain, is not changed by the protracted MET treatment schedule adopted in our experiments.
To definitively establish whether the RELN and GAD 67 promoter demethylation process in MET-treated mice is slow because of a direct or indirect increase of DNMT activity, we used procainamide in doses and treatment schedules that effectively inhibited DNMT1 activity (Fig. 7) . Procainamide failed to accelerate the demethylation of RELN and GAD 67 promoters (Fig. 7) .
Taken together, the available data suggest that direct or indirect changes in DNMT activity are not responsible for the long time course of RELN and GAD 67 promoter demethylation.
In the mammalian neocortex, RELN and GAD 67 are expressed in GABAergic neurons but not in pyramidal neurons or glial cells (12) . Because the protracted administration of MET induces RELN and GAD 67 expression down-regulation in GABAergic neurons and because after protracted administration, MET withdrawal results in a reversal of this downregulation (Fig. 5) , it is probable that at least in part, methylation and demethylation of RELN and GAD 67 promoters may occur in differentiated nondividing GABAergic neurons. Hence, under physiological conditions in the CNS, RELN and GAD 67 promoter demethylation does not appear to be a passive process dependent on cell replication or differentiation.
The experiments with VPA and MS-275 strongly suggest that DNA demethylation can be dramatically activated by increasing histone acetylation. In fact, VPA and MS-275 administered to mice after the termination of protracted MET treatment elicit a demethylation of RELN and GAD 67 promoters in 48 -72 h (Figs. 3 and 4) . At the doses used here, VPA and MS-275 both increase the content of nuclear acetylhistone-3 bound to RELN and GAD 67 promoters by 40 -50% (29) , suggesting that a putative histone code modification may participate in the modulation of DNA demethylation by these chemically unrelated drugs.
The action of VPA and MS-275 on RELN and GAD 67 promoter demethylation could be elicited by (i) an inhibition of DNMT activity or (ii) the activation of a DNA demethylase.
Two sets of data suggest that the accelerated RELN and GAD 67 promoter demethylation induced by treatment with VPA or MS-275 may be directly or indirectly related to an induction of DNA demethylase rather than to a reduced DNMT1 activity: (i) reduction of DNMT1 activity with procainamide fails to activate demethylation of the hypermethylated RELN and GAD 67 promoters, and (ii) VPA fails to block SAM biosynthesis, and in fact may even favor its biosynthesis (22, 24) . Hence, we believe that in mice the mechanism by which the recovery of RELN and GAD 67 expression is accelerated by VPA or MS-275 after MET withdrawal could be related to the induction of a putative DNA demethylase activity. The data agree with a previous report of Detich et al. (28) , demonstrating that VPA triggers a replicationindependent active demethylation of DNA.
Because the biochemical nature of a putative DNA demethylase in mammalian cells is not yet clearly established (26-28, 33, 34) , it is impossible to determine whether the accelerated RELN and GAD 67 promoter demethylation elicited in the mouse FC by HDAC inhibitors is the result of DNA demethylase activation or of an induction of DNA demethylase biosynthesis. In the future, the characterization of an inducible active demethylation mechanism in the mammalian brain offers an attractive possibility of discovering new classes of drugs that are active on epigenetic mechanisms by modulating the function of putative DNA demethylases. Obviously, these drugs will be extremely valuable in Fig. 7 . Procainamide prevents the MET-induced increase in the amount of FC RELN and GAD 67 promoter immunoprecipitated with MeCP2 antibody but fails to facilitate its reversal after MET withdrawal. In the first group of experiments (A and B), mice were first treated with MET (5.2 mmol/kg s.c. twice a day for 7 days) (F) to obtain a robust hypermethylation of RELN and GAD 67 promoters, or VEH (twice a day for 7 days) (E). After MET withdrawal, one group of mice received VEH (■) and one group received procainamide (ᮀ) (0.29 mmol/kg s.c. four times a day) for 13 days. Measurements of RELN promoters (A) and GAD 67 promoters (B) are reported. In the second group of experiments (C and D), after MET withdrawal mice were first treated with VEH (■), or procainamide (ᮀ) for 7 days, both groups received MET again, together with VEH (■) or procainamide (ᮀ) for an additional 7 days [measurements of RELN promoters (C) and GAD 67 promoters (D) are reported]. The data represent mean Ϯ SE of three to five mice. * , P Ͻ 0.01 vs. MET-treated group at day 0 (ANOVA followed by Dunnett's test). Methods were as in Fig. 2. under UV illumination. Data were presented as the ratio of optical density of the methylated band over the unmethylated ones. In the preliminary studies, we established that the ratio of unmethylated to methylated PCR-amplified products is maintained in a linear range between 28 and 33 cycles. Hence, for routine experiments, 30 cycles were used. For each sample analyzed, the assays, including extraction, bisulfate treatment, and PCR, were repeated at least three times. Genomic DNA methylated with SssI methylase in vitro served as a positive control for the methylated cytosines in the RELN promoters. Genomic DNA served as an additional control to indicate that the primers for methylated RELN and GAD 67 did not amplify the unmethylated DNA.
Statistical Analysis. All results were expressed as mean Ϯ SE. Student's t test and one-way ANOVA followed by the Dunnett's multiple comparison test were used to assess the significance of the differences between groups. The criterion for significance was P Ͻ 0.05 or 0.01. The criterion for significance was adjusted for multiple tests on the same data set.
